Bio/Pharma Outsourcing Innovation eBook
Read the article:
CROs Gaining a Competitive Edge
Read the eBook:
Pharmaceutical Technology’s Bio/Pharma Outsourcing Innovation eBook
OR WAIT null SECS
© 2024 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Shifting toward more technological solutions and ensuring a greater understanding of the workforce’s needs will give both CROs and sponsors a market advantage.
Advanced therapeutic medicinal products (ATMPs) are experiencing a boom, with the global pipeline continuing to experience growth and more than 3700 ATMPs currently under development, according to data from the American Society of Gene and Cell Therapy. However, progressing such complex therapies that target niche disease areas through to commercialization produces a unique set of challenges.
Read the article:
CROs Gaining a Competitive Edge
Read the eBook:
Pharmaceutical Technology’s Bio/Pharma Outsourcing Innovation eBook
Critically, the technical expertise required for the clinical research of ATMPs is something that can be lacking for developers in-house, driving demand for contract research organizations (CRO). In fact, the cell and gene therapy CRO market is forecast to experience continued and consistent growth until 2035.
In this feature, Rhonda Henry, president of Emmes BioPharma; Ching Tian, chief innovation officer, Emmes; and Raja Sharif, CEO Hataali, detail the challenges facing biopharma companies developing ATMPs and the role that CROs play in gaining a market advantage.
Read this article in Pharmaceutical Technology's February 2023 Bio/Pharma Outsourcing Innovation eBook.
Felicity Thomas is European/senior editor for Pharm Tech Group
Pharmaceutical Technology
eBook: Bio/Pharma Outsourcing Innovation
February 2023
Pages: 12–15
When referring to this article, please cite it as Thomas, F. CROs Gaining a Competitive Edge. Pharmaceutical Technology's Bio/Pharma Outsourcing Innovation eBook (February 2023).